Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth
L’IA multimodale transforme la manière dont les utilisateurs exploitent l’intelligence artificielle. Capable de comprendre et de combiner plusieurs formats
This under-the-radar consumer discretionary stock boasts a Superscore of 80 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.
Executives from Bitcoin mining and digital infrastructure companies said access to energized power, land and data-center development capabilities is creating an opportunity to serve growing artificial intelligence infrastructure demand, while also presenting significant construction, financing and r
Recent pullbacks have created potential opportunities in several quality TSX stocks. Other than dividends, they also offer potential upside if their valuations recover.
Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility.
Speaking at
Customer experience is influenced by far more than the products or services a business provides. In restaurants, retail stores, hotels, cafés, and other ho
Choosing the right hair salon services can make a significant difference in how your hair looks, feels, and fits into your everyday lifestyle. Whether you
Turning Smartphone Screens into Reward HubThe landscape of mobile amusement has tilt dramatically terminated the retiring few years. Multitude no longer po
Dave & Buster's Entertainment (NASDAQ:PLAY) reported lower second-quarter revenue and earnings but said same-store sales trends improved during July and the early weeks of its third quarter as the company pursues a “back-to-basics” strategy centered on traffic, value and store execution.
Revenu
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected data updates across several pipeline programs by the end of 2026.
Kulkarni said the company’s stra
Citigroup (NYSE:C) Chief Financial Officer Gonzalo Luchetti said the bank expects full-year return on tangible common equity, or ROTCE, to finish slightly above the high end of its previously stated 10% to 11% range, citing continued momentum across its markets, banking, services and consumer busine
Kestra Medical Technologies (NASDAQ:KMTS) reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter. The company raised its full-year revenue outloo
Radiant Logistics (NYSEAMERICAN:RLGT) reported higher fourth-quarter revenue, profit and adjusted EBITDA for the fiscal quarter ended June 30, 2026, as its U.S. forwarding operations, domestic services and international air freight business contributed to growth.
Net income attributable to Radiant
Evertz Technologies (TSE:ET) reported fiscal 2027 first-quarter revenue of CAD 118.3 million, up 5.5% from CAD 112.0 million a year earlier, as growth in software and services and international sales offset a slight decline in hardware revenue.
For the quarter ended July 31, 2026, the company recor
American Battery Technology (NASDAQ:ABAT) reported a more than 400% increase in fiscal 2026 revenue to $21.7 million, driven by higher throughput at its first lithium-ion battery recycling facility, expanded byproduct manufacturing and improved product pricing, Chief Executive Officer and Chief Tech
MindWalk (NASDAQ:HYFT) reported first-quarter fiscal 2027 revenue of CAD 3.8 million, up 21% from CAD 3.2 million a year earlier, as the company continued investing in commercialization of its ReefIQ biological-data platform and expanded its drug discovery partnership model.
Gross margin increased
Level Up Your Smartphone IncomeThe digital landscape has transformed dramatically over the past few years, become ordinary roving devices into potential po
On Sept. 14, 2026, CEO Brian Moynihan flagged weaker trading performance and softer dealmaking fees, keeping investors focused on capital-markets sensitivity.
